Oesophageal disease patients can have similar symptoms — but their diseases may be different. This means tests aren't always conclusive and treatment isn't always effective:
Our solutions help you objectively evaluate the root cause of oesophageal motility disorders and GORD:
Download and access the EndoflipTM Impedance Planimetry System Protocole & Interpretation white paper
Learn how our comprehensive portfolio can help you care for patients across the care continuum — from GORD to Barrett's oesophagus.
1. Laine, Goldmann et al. In the clinic: gastroesophageal reflux disease. Annals of Internal Medicine. 2008 Aug 5; ITC2: 1-16.
2. Kahrilas PJ. Gastroesophageal reflux disease. N Engl J Med. 2008; 359: 1700-7.
3. Ronkainen et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005; 129: 1825-1831.
4. Kawamura O, Hosaka H, Shimoyama Y et al. Evaluation of proton pump inhibitor resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring. Digestion. 2015;91(1):19-25.
5. Herregods, T. V. K., et al. Patients with refractory reflux symptoms often do not have GERD: Neurogastroenterology & Motility. 2015; 27(9): 1267-1273.
6. Ahuja NK, Agnihotri A, Lynch KL, et al. Esophageal distensibility measurement: impact on clinical management and procedure length. Diseases Of The Esophagus: Official Journal Of The International Society For Diseases Of The Esophagus. 2017;30(8):1-8.
7. Triadafilopoulos G, Zikos T, Regalia K, et al. Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms. Digestive Diseases And Sciences. 2018;63(10):2673-2680. doi:10.1007/s10620-018-5183-4.